Peter Martin, MD, discusses the potential role of LOXO-305 in mantle cell lymphoma.
Peter Martin, MD, chief, the Lymphoma Program, Meyer Cancer Center, associate professor of medicine, Weill Cornell Medicine, discusses the potential role of LOXO-305 in mantle cell lymphoma (MCL).
LOXO-305 is an investigational, selective, non-covalent BTK inhibitor, says Martin. During the 2020 ASH Annual Meeting and Exposition, findings from the phase 1/2 BRUIN trial demonstrated an investigator-assessed objective response rate of 52% with LOXO-305 in patients with MCL. Additionally, although multiple BTK inhibitors are approved for the treatment of patients with MCL, LOXO-305 demonstrated utility in treating patients who progressed on prior BTK inhibitors, Martin explains.
Currently, the mechanism of action that causes LOXO-305 to confer activity in patients who received prior BTK inhibitors is unknown, but hypotheses are emerging, Martin says. Regardless, the activity observed with LOXO-305 suggests the agent could be an effective treatment for patients with prior exposure to BTK inhibitors. Additionally, the agent could potentially compete with approved BTK inhibitors because it demonstrated a tolerable safety profile across multiple B-cell malignancies, concludes Martin.